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ABSTRACT 
Objective 
Targetting remission in rheumatoid arthritis (RA) improves health related quality of life 
(HRQoL) and disability. However, the impacts of different remission criteria and durations 
and their frequencies are uncertain. Our observational study assessed these factors. 
 
Methods 
We recruited RA patients with disease durations <10 years, stable suppressive therapies and 
stable disease activity scores for 28 joints using ESR (DAS28-ESR) ≤3.2. Intermittent and 
sustained remisisons were classified using DAS28ESR, simple disease activity index (SDAI) 
and ACR/EULAR Boolean criteria. HRQoL, measured using SF-36, fatigue, EuroQol and 
health assessment questionnaire (HAQ) was compared using time-integrated areas under the 
curve (AUC). 
 
Results 
104 patients were enrolled and followed for 12 months. DAS28-ESR remissions were 
intermittent in 42%, sustained in 47% and absent in 11%. Boolean remissions were 
intermittent in 38%, sustained in 10% and absent in 52%.  Baseline remissions by all criteria 
significantly improved HAQ, Euroqol, SF36 and fatigue scores compared with low disease 
activity (LDAS); AUCs showed significant benefits for all HRQoLs persisted over 12-
months. Boolean remissions achieved most benefits. Over time all remisison states gave 
significantly better HRQoL scores than LDAS. Sustained DAS28ESR and SDAI remisisons 
improved HRQoL more than intermittent remissions. Sustained and intermittent Boolean 
remissions gave similar improvements. Analysis of SF-36 domains showed even sustained 
Boolean remissions failed to optimise pain and fatigue.  
 
Conclusions 
All remissions improve HRQoL but different criteria have variable impacts. Boolean 
remission had most impact but occurred least. There are trade-off between otpimising 
individual impacts (Boolean remissions) and achieving maximal overall impacts (DAS28-
ESR remissions).  
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INTRODUCTION 
Rheumatoid arthritis (RA) is characterised by both inflammatory synovitis and long term 
disability and impaired health-related quality of life (HRQoL) [1,2]. Patients focus on their 
impaired HRQoL, which can be assessed by a variety of validated instruments including 
generic measures such as Medical outcomes study 36-Item Health Survey forms (SF-36), 
EuroQol and Functional Assessment of Chronic Illness Therapy (FACIT-F) and disease-
specific measures like the Health Assessment Questionnaire (HAQ) [3].  
 
Targeting remission when treating RA, encapsulated in treat-to-target management [4,5], is 
considered to maximise HRQoL and minimise disability [6,7]. There is strong evidence that 
effective treatment of active RA decreases disability [8,9]. There is also considerable 
evidence treatment improves HRQoL [10-13]. Radner et al [14,15] have provided 
observational evidence and an analysis of clinical trial data that shows remission in general 
and sustained remission in particular benefit HRQoL. Other observational study data supports 
the concept that sustained remission most benefits disability [16]. However, many 
chanllenges remain when targeting remission. One issue is that some patients have 
histological evidence of persisting inflammation despite achieving clinical remission [17]. 
Another complexity is the varying perspectives of patients about what they want from 
treatment [18]. 
 
The key factors influencing how RA remission benefits HRQoL are their type, duration and 
frequency and considerable uncertainty remains about their relative importance in assessing 
treatment benefits. The use of less arduous remission criteria has been the subject of critical 
comment [19]. We examined all three factors in a prospective cohort of treated RA patients 
with stable low disease activity states. We evaluated three questions about how remission 
affects HRQoL. Firstly do different definitions of RA remission have different impacts on 
HRQoL? Secondly how important are sustained as opposed to intermittent remissions? 
Finally what is the relative frequency of different forms of remission? 
 
PATIENTS AND METHODS 
Patients 
We recruited consecutive consenting adult RA patients who had been diagnosed using the 
1987 revised ACR criteria and were currently attending three rheumatology centres in south 
London who met the following criteria. Recruitment period was from 2009 – 2011. Firstly, 
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they had disease durations of less than 10 years from the date of diagnosis. Secondly they had 
received stable doses of disease modifying anti-rheumatic (DMARD) or biologic therapies 
for over 6 months. Thirdly their disease activity scores for 28 joints assessed using the 
erythrocyte sedimenatation rate (DAS28-ESR) had been ≤3.2 for one month or longer.  
 
Assessments 
Initial data was collected about demographics, disease duration and current treatment. 
Disease activity assessments were made initially and every three months for one year to 
assess the following remission criteria: DAS28-ESR (erythrocyte sedimentation rate), 
DAS28-CRP (C-reactive protein), simple disease activity index (SDAI), clinical disease 
activity index (CDAI) and American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) Boolean remission criteria [20, 21]. 
 
Health Assessment Questionnaire Disability Index (HAQ-DI) [22]. The Medical Outcomes 
Study 36-Item Short-Form Health Survey (SF36) [23] including its eight domains and two 
sub-scales. The EQ-5D, which is also known as EuroQol [24], recorded as a single score, and 
the Functional Assessment of Chronic Illness Therapy (FACIT-F) [25] for recording self-
reported fatigue. These outcomes were all measured every 3 months over the 12 month 
period of follow up. 
 
Definitions Of Remission 
Internationally agreed criteria were used [19,20]. Point remission at baseline was DAS28-
ESR <2.6, DAS28-CRP <2.32, SDAI ≤ 3.3 and CDAI ≤ 2.8. ACR/EULAR Boolean 
remission was defined as TJC, SJC, CRP (mg/dl) and patient VAS (0-10cm) all ≤1. Low 
disease activity State (LDAS) at baseline was defined as patients not in remission by any 
definition with DAS28-ESR ≤3.2. Sustained remission (SR) was defined as achieving 
remission at all visit time-points, intermittent remission (IR) defined as achieving remission 
in at least 1 visit time-point, but not all. No remission (NR) was defined as never achieving 
remission by any clinical definition at any visit time-point over the 12 month period of 
follow-up. 
 
Statistical Analysis 
STATA 11.2 (StataCorp, College Station, TX, USA) was used for statistical analysis. 
Individual variables were assessed descriptively as median values and interquartile ranges 
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(IQR).  To assess the impact of remission on HRQoL over 1 year, time-integrated values 
were calculated using area under the curve (AUC). These were computed using GraphPad 
Prism software using the trapezoidal method. Last observations carried forward (LOCF) 
method was used to handle missing data. Comparisons of these HRQoL measures between 
remission vs non- remission at baseline and between NR vs IR, IR vs SR and NR vs IR were 
performed using Mann-Whitney test.  
 
Ethics Approval 
The study was approved by the local ethics committee and conducted according to the 
guidelines of the Declaration of Helsinki (REC:09/H0803/154, Wandsworth Research Ethics 
Committee). Written informed consent was obtained from all participants. 
 
RESULTS 
Patient Cohort And Remission Rates 
104 patients were enrolled of median age 56 years and median disease duration 45 months. 
Their baseline characteristics are shown in Table 1.  
 
At baseline 67/102 (66%) were in DAS28-ESR remission and 35/102 (34%) were in LDAS 
states. Other remission criteria at baseline were met by 58 (59%) for DAS28-CRP remission, 
45 (46%) for SDAI remission, 47 (46%) for CDAI remission and 30 (30%) for Boolean 
remission.  
 
During 12 months follow up intermittent DAS28-ESR remissions occurred in 42% and 
sustained remission in 47% patients; only 11% of patients never achieved a DAS28-ESR 
remission. In contrast intermittent Boolean remissions occurred in 38% and sustained 
remission in only 10%; 52% of patients never achieved a Boolean remission. Other remission 
criteria were achieved by intermediate numbers of patients; the findings are summarised in 
Figure 1.  
 
Baseline Remission Status 
Comparing patients in baseline remission by DAS28ESR, SDAI or Boolean remission 
criteria with patients in low disease activity states (LDAS) showed patients in initial 
remission by all three criteria had significantly better baseline HAQ, Euroqol, FACIT F and 
SF36 scores than LDAS patients (Table 2). Those patients in remission at baseline also had 
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better AUC assessments of all HRQoL outcomes over the ensuing 12 months compared to 
LDAS patients.  
 
The different remission criteria had variable effects on different HRQoL outcomes. The 
impacts on HRQoL were greatest with Boolean remission and least with DAS28-ESR 
remissions. 
 
Intermittent And Sustained Remissions 
Both intermittent and sustained remission states using DAS28-ESR, SDAI and Boolean 
criteria gave significantly better HRQoL scores than LDAS (Figure 2). With both 
DAS28ESR and SDAI, HRQoL was significantly better with sustained remissions than with 
intermittent remissions. With Boolean criteria both sustained and intermittent remissions 
gave similar improvements; Boolean remissions also gave the best overall benefits in 
improving HRQoL.  
 
SF36 components 
The improvements for each of the eight SF-36 domains with different remssion criteria is 
shown using spidergrams in Figure 3. The AUCs were better for all domains when patients 
achieved remission. DAS28-ESR and SDAI sustained remissions gave greater improvements 
than intermittent remissions. The improvements across the different SF-36 domains were 
greatest with Boolean remissions; and intermittent and sustained Boolean remissions 
achieved similar improvmemnts. However, even with Boolean remissions vitality, general 
health and bodily pain domains were not optimised.  
 
DISCUSSION 
We have confirmed that RA patients who achieve remissions at both single time points or 
sustained remissions have better HRQoL than patients who only achieve low disease activity 
states, in keeping with previous reports [6-16, 26-28]. However, we have also shown that not 
all remission criteria are equivalent. Achieving Boolean remissions has the greatest impact on 
HRQoL, DAS28-ESR remissions have the least impact and SDAI remissions have an 
intermediate impact. We found that with Boolean remissions most aspect of HRQoL are 
normalized; fatigue, pain and general health are the main exceptions and are not completely 
controlled. Sustained and intermittent remission had similar benefits with Boolean 
remissions, but only 38% of patients achieved any Boolean remission. The situation was 
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different with DAS2-ESR remissions. Although they improved most aspects of HRQoL 
compared to low disease activity, their but impacts were relatively modest, and there were 
substantial differences between sustained and unsustained remission. Nevertheless 89% of 
patients had some periods in DAS28 remission. 
 
The inter-relationships between HAQ scores and remissions are complex. Firstly, there is 
some evidence that initial HAQ scores predict subsequent remissions, with patients having 
low HAQ scores being more likely to achieve remissions after treatment [29,30]. Secondly, 
we have found that HAQ scores are significantly lower when patients achieve remission by 
any criteria than when they are in low disease activity states. This finding replicates several 
other published studies. [31,32]. Thirdly, there is debate about the optimal target for HAQ 
scores. Molenaar et al [33] suggested HAQ scores <0.5 were optimal targets. However, we 
found median HAQ scores with SDAI and Boolean remissions were zero, suggesting there 
may be floor effects with low disease activity states and that HAQ scores of 0.5 may be 
suboptimal as a target. Finally the relationship of HAQ to remission may be influenced by the 
type of patients studied. Analysis of HAQ scores in patients from the DREAM cohort who all 
received biologic therapy, had somewhat higher HAQ scores when in remission [34] than the 
patients we studied.  However, they are all likely to have overall worse severities than the 
more heterogenous patient group we studied. Interestingly the median HAQ value in our 
patients was also lower than the original cut-off for predictive validity of the ACR/EULAR 
Boolean criteria [20]. 
 
The assessment of HRQoL using SF36 and EQ5D is more complex. Both assessments have 
been used in RA and are able to detect changes in health status [35,36]. They both improve 
with effective treatments and have been most often studied in patients receiving biologics. 
Although deeper remissions, particularly Boolean remissions, gave the greates improvements 
in these measures, we found vitality, general health and bodily pain SF-36 domains were not 
optimised in any patient group. This reflects previously reported failure to minimise pain 
levels in RA patients in DAS28 remission reported by Lee et al [37]. FACIT-F assessments, 
which focuss on fatigue showed a similar pattern of incomplete control, which has also 
recently been reported in patients treated with biologics who have achieved remissions [38]. 
These findings imply that achieving remission by intensive drug treatment may not always 
normalise HRQoL in RA. One explanation for this finding is the impact of comorbidities [39-
41], which we did not assess in detail. It is also likely that in established RA it may be 
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impossible to reverse the impact of the disease; as a consequence there is greatest emphasis 
on achieving remission by early intensive treatment. 
 
The strengths of our study include its relatively large size and its complete 12 months regular 
follow up in a homogenous clinical population receiving similar treatment approaches. The 
observations were made by a small number of trained collaborating clinicians with good inter 
and intra-observer reproducibility in their assessments and a range of HRQoL instruments 
were used. It also has several limitations. Firstly, relatively few achieved sustained Boolean 
remissions, limiting an assessment of intense remissions. Secondly, as different remission 
criteria describe overlapping patient groups, the analytical approaches available are limited. 
Thirdly, we studied patients seen in specialist centres; community-based patients might show 
different inter-relationships between disease activity and HRQoL. Finally, due to the 
observational design of this study, as well as the small sample size, we were unable to 
address treatment effects on HRQoL within the remission groups.  
 
There remains a paradox in setting the target for treating RA intensively. How low and how 
sustained should the target be set [42]? The benefits of Boolean remission, which improves 
HRQoL and disability greatest but still has incomplete effects on fatigue and pain, must be 
set against its relative rarity [43,44]. It is possible that not all patients can ever achieve 
Boolean remission; and there is evidence that different remission criteria have different 
predictive factors [45]. It is also likely that complete remission is an appropriate target in 
early RA [46] and less intense remissions reasonable in established disease. Our study design 
did not focus on a comparison of early and established disease, but there is strong evidence 
remission rates are higher when patients with early disease receive intensive treatments. [47]. 
Current expert opinion continues to have doubts about the relative benefits of aiming for 
LDAS or different remission criteria [48]. Our findings highlight the nature of this 
uncertainty, which reflects the benefits for groups of patients versus individual patients. 
Future prognostic markers may allow a resolution of doubts by identifying individual targets 
for patients in which bespoke targets replace global aims. Although this is currently a future 
aspiration, it might be sensible to start using it in different disease durations and to mainly 
focus on obtaining Boolean remission in early RA patients beginning intensive treatment 
strategies. 
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Table 1: Baseline Characteristics Of Patients 
 
Patient Characteristics  
Age, Median (IQR) years 56 (47, 69) 
Disease Duration, Median (IQR) months 45 (23, 75) 
Female (Percent) 63% 
IgM RF Positive (Percent) 88% 
ACPA Positive (Percent) 72% 
Ethnicity 
Caucasian 74% 
Asian 7% 
Afro-carribean 19% 
TJC28, Median (IQR) 0 (0,1) 
SJC28, Median (IQR) 0 (0,1) 
ESR, Median (IQR) 8 (4, 16) 
Patient Global, Median (IQR) (0-100mm) 18 (10, 35) 
DAS28ESR, Median (IQR) 2.10 (1.40, 2.78) 
DAS28CRP, Median (IQR) 2.15 (1.79, 2.72) 
SDAI, Median (IQR) 3.60 (1.70, 7.56) 
CDAI, Median (IQR) 3.20 (1.20, 7.20) 
HAQ, Median (IQR) 0.13 (0, 0.75) 
EQ5D, Median (IQR) 0.80 (0.69, 0.88) 
EQ5D VAS, Median (IQR) 80 (70,90) 
FACIT-F, Median (IQR) 42 (35, 47) 
SF36 MCS, Median (IQR) 52 (44, 58) 
SF36 PCS, Median (IQR) 44 (38, 52) 
Erosive Disease (Percent) 52% 
Erosive Progression (Percent)  14% 
Treatments 
Methotrexate 87% 
Sulphasalazine 27% 
Hydroxychloroquine 31% 
Leflunomide 4% 
Prednisolone 3% 
Combination disease modifying therapy 43% 
Tumour Necrosis Factor Inhibitors 16% 
Table 2: Impact Of Baseline LDAS and Remission Status On Baseline And AUC HRQoL 
 
HRQoL LDAS DAS28 Remission SDAI Remission Boolean Remission 
 Level Level Significance Level Significance Level Significance 
Baseline 
HAQ 0.75 (0.5,1.38) 0 (0, 0.5) <0.001 0 (0, 0.125) <0.001 0 (0, 0.125) <0.001 
Euroquol 0.69 (0.59,0.76) 0.80 (0.69, 1.00) 0.024 1.00 (0.80, 1.00) <0.001 1.00 (0.80, 1.00) <0.001 
FACIT-F 35 (31, 38) 43 (38, 47) <0.001 46 (42, 50) <0.001 46 (43, 50) <0.001 
SF36 PCS 39 (34, 43) 48 (40, 53) <0.001 51 (46, 55) 0.001 52 (48, 55) <0.001 
SF36 MCS 49 (41, 53) 54 (47, 58) 0.021 57 (51, 58) <0.001 57 (51, 58) 0.002 
Area Under Curve 
HAQ AUC 10.3 (4.0,14.1) 1.2 (0, 6.6) <0.001 0.28 (0, 1.8) <0.001 0.43 (0, 188) <0.001 
Euroquol AUC 8.7 (7.7, 9.3) 9.9 (8.7, 11.4) <0.001 10.6 (9.5,11.7) <0.001 11.1 (9.6, 12.0) <0.001 
FACIT-F AUC 414 (349, 488) 537 (455 575) <0.001 553 (492, 589) <0.001 569 (488, 594) 0.001 
SF36 PCS AUC 467 (430, 512) 588 (513 638) <0.001 622 (554, 695) <0.001 622 (585, 655) 0.007 
SF36 MCS AUC 552 (500, 648) 618(557, 674) 0.005 649 (583, 691) 0.001 663 (597, 689) <0.001 
 
Comparing low disease activity state at baseline (LDAS) with baseline DAS28ESR, SDAI and Boolean remission  
All values are reported as median (IQR). HRQoL = Health related quality of life, SF36 = short form 36, PCS = physical component score, MCS 
= mental component score, HAQ = health assessment questionnaire, AUC = area under the curve. 
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Figure 1. Frequency Of Intermittent Remission And Sustained Remission Using Different Criteria 
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Figure 2. Impact Of Intermittent And Sustained Remission By DAS28, SDAI and Boolean Criteria On HRQoL Area Under Curve 
 
  
Medians with interquartile and minimum and maximum ranges. IR = intermittent remission, SR = sustained remission 
NS = Non-Significant, * =  P ≤ 0.05, **  = P ≤ 0.01, *** =  P ≤ 0.001, **** =   P ≤ 0.0001 using Mann-Whitney test  
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Figure 3. Spidergrams Of SF-36 Domains In Patients Without Remissions And With Intermittent And Sustained Remissions 
 
  
A=DAS28 remission, B=SDAI remission, C=Boolean remission. Values expressed as median AUC values 
PR = physical functioning, RP = Role-physical, BP = bodily pain, GH = general health, VT = vitality, SF = social functioning,  
RE = Role-emotional, MH = mental health 
  
